Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Rami Komrokji, MD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Rachid Baz, MD, Taiga Nishihori, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, William Dalton, PhD MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 2129.

https://doi.org/10.1182/blood.V124.21.2129.2129

Published: 2014

Journal Articles

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeff E Lancet, MD, Marta Olesnyckyj, Laurie Kenvin, BSN, RN, Robert D. Knight, MD, William Dalton, PhD MD, Alan F. List, MD, Rami Komrokji, MD

Blood (2014) 124 (21): 413.

https://doi.org/10.1182/blood.V124.21.413.413

Published: 2014

Journal Articles

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Paul Richardson, Sundar Jagannath, Mohamad Hussein, James Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William Bensinger, Ashraf Z. Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight, Kenneth C. Anderson

Blood (2009) 114 (4): 772–778.

https://doi.org/10.1182/blood-2008-12-196238

Published: 2009

Journal Articles

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Michael Wang, Meletios A. Dimopoulos, Christine Chen, M. Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Donna M. Weber

Blood (2008) 112 (12): 4445–4451.

https://doi.org/10.1182/blood-2008-02-141614

Published: 2008

Journal Articles

Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status

Asher Chanan-Khan, MD, Meletios A Dimopoulos, MD, Donna M. Weber, Andrew Spencer, Michel Attal, MD, Andrew Belch, MD, Alessandro Corso, Tommy Fu, Jerome B. Zeldis, MD, Marta Olesnyckyj, Robert D. Knight, MD, Sagar Lonial, MD

Blood (2008) 112 (11): 3701.

https://doi.org/10.1182/blood.V112.11.3701.3701

Published: 2008

Journal Articles

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Jesús F San Miguel, Meletios A Dimopoulos, MD, Edward A. Stadtmauer, MD, S. Vincent Rajkumar, MD, David Siegel, Marie-Laure Bravo, Marta Olesnyckyj, Robert D. Knight, MD, Jerome B. Zeldis, MD, Jean-Luc Harousseau, Donna M. Weber

Blood (2008) 112 (11): 3702.

https://doi.org/10.1182/blood.V112.11.3702.3702

Published: 2008

Journal Articles

Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).

Jesus F. San Miguel, Meletios Dimopoulos, Donna Weber, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, Vincent Rajkumar

Blood (2007) 110 (11): 2712.

https://doi.org/10.1182/blood.V110.11.2712.2712

Published: 2007

Journal Articles

ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).

Asher A. Chanan-Khan, Meletios Dimopoulos, Donna Weber, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, Jesus F. San Miguel

Blood (2007) 110 (11): 2721.

https://doi.org/10.1182/blood.V110.11.2721.2721

Published: 2007

Journal Articles

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

Jean-Luc Harousseau, Donna Weber, Meletios Dimopoulos, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, David Siegel

Blood (2007) 110 (11): 3598.

https://doi.org/10.1182/blood.V110.11.3598.3598

Published: 2007

Journal Articles

Prolonged Overall Survival with Lenalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma.

Donna Weber, Robert Knight, Christine Chen, Andrew Spencer, Zhinuan Yu, Jerome Zeldis, Marta Olesnyckyj, Meletios Dimopoulos

Blood (2007) 110 (11): 412.

https://doi.org/10.1182/blood.V110.11.412.412

Published: 2007

Journal Articles

Lenalidomide/Dexamethasone Improves Response and Prolongs Time to Progression, Even in Patients with IgA Multiple Myeloma: A Sub-Analysis of the MM-009/010 Studies.

Robert Foa, Donna Weber, Meletios Dimopoulos, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, Robert Knight, Asher Alban Chanan-Khan

Blood (2007) 110 (11): 4839.

https://doi.org/10.1182/blood.V110.11.4839.4839

Published: 2007

Journal Articles

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Edward Stadtmauer, MD, Donna Weber, MD, M. Dimopolous, MD, Andrew Belch, MD, Michel Attal, MD, Miles Prince, MD, Marta Olesnyckyj, Zhinuan Yu, Jerome Zeldis, MD, Robert Knight, MD

Blood (2006) 108 (11): 3552.

https://doi.org/10.1182/blood.V108.11.3552.3552

Published: 2006

Journal Articles

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Michael Wang, MD, Robert Knight, MD, Melitios Dimopoulos, MD, David Siegel, MD, S. Vincent Rajkumar, MD, Thierry Facon, MD, Raymond Alexanian, MD, Zhinuan Yu, PhD, Jerome Zeldis, MD, PhD, Marta Olesnyckyj, Donna Weber, MD

Blood (2006) 108 (11): 3553.

https://doi.org/10.1182/blood.V108.11.3553.3553

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

Asher Alban Chanan-Khan, MD, Zhinuan Yu, PhD, Donna Weber, MD, Christine Chen, MD, Ruben Niesvizky, MD, Andrew Spencer, MD, Michel Attal, MD, Andrew Belch, MD, Miles Prince, MD, Marta Olesnyckyj, Robert Knight, MD, Jerome Zeldis, MD, Meletius Dimopoulos, MD

Blood (2006) 108 (11): 3554.

https://doi.org/10.1182/blood.V108.11.3554.3554

Published: 2006

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

S. Vincent Rajkumar, MD, Mohamad Hussein, John Catalano, Wieslaw Jedrzejcak, Svetlana Sirkovich, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerry Zeldis, Joan Blade

Blood (2006) 108 (11): 795.

https://doi.org/10.1182/blood.V108.11.795.795

Published: 2006

Journal Articles

Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.

Donna Weber, MD, Michael Wang, M.D., Christine Chen, M.D., Andrew Belch, M.D., Edward A. Stadtmauer, M.D., Ruben Niesvisky, M.D., Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, M.D., Robert D. Knight, M.D., Meletios Dimopoulos, M.D.

Blood (2006) 108 (11): 3547.

https://doi.org/10.1182/blood.V108.11.3547.3547

Published: 2006

Journal Articles

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Donna Weber, Meletius Dimopoulos, Christine Chen, Reuben Niesvizky, Michael Wang, Andrew Belch, Michel Attal, Andrew Spencer, Miles Prince, Marta Olesnyckyj, Jerome Zeldis, Zhinuan Yu, Robert Knight

Blood (2006) 108 (11): 3551.

https://doi.org/10.1182/blood.V108.11.3551.3551

Published: 2006

Journal Articles

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Blood (2006) 108 (10): 3458–3464.

https://doi.org/10.1182/blood-2006-04-015909

Published: 2006

Journal Articles

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Paul Richardson, MD, Sundar Jagannath, MD, Mohamad Hussein, MD, James Berenson, MD, Seema Singhal, MD, David Irwin, MD, Stephanie F. Williams, MD, William Bensinger, MD, Ashraf Z. Badros, MD, Robert Vescio, MD, Laurie Kenvin, BSN, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Herbert Faleck, DO, Jerome Zeldis, MD, Robert Knight, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 1565.

https://doi.org/10.1182/blood.V106.11.1565.1565

Published: 2005

Journal Articles

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Meletios A. Dimopoulos, MD, Andrew Spencer, MBBS, Michael Attal, MD, PRD, Miles Prince, MD, Jean-Luc Harousseau, MD, Anna Dmoszynska, MD, PhD, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Jerome Zeldis, MD, Robert Knight, MD

Blood (2005) 106 (11): 6.

https://doi.org/10.1182/blood.V106.11.6.6

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Subsequent Primary Malignancies Among Multiple Myeloma Patients Treated with or without Lenalidomide

Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).

ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).

Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response.

Prolonged Overall Survival with Lenalidomide Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma.

Lenalidomide/Dexamethasone Improves Response and Prolongs Time to Progression, Even in Patients with IgA Multiple Myeloma: A Sub-Analysis of the MM-009/010 Studies.

Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma.

Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.

Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.

A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma.

Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.

Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM).

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only